Status:
UNKNOWN
Clinical Study of MAK Immune Cells in the Treatment of PHC
Lead Sponsor:
Zhongnan Hospital
Conditions:
Primary Hepatocellular Carcinoma
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The investigators will plan to recruit 20 patients with liver cancer CNLC stage Ⅲa and Ⅲb who are older than 18 years old. Peripheral blood mononuclear cells were obtained and then the MAK(Mixed-activ...
Detailed Description
The investigators will plan to recruit 20 patients with liver cancer CNLC stage Ⅲa and Ⅲb who are older than 18 years old. Peripheral venous blood was collected twice (50-60ml/time, 2 times, 1 week ap...
Eligibility Criteria
Inclusion
- Age over 18 years old, regardless of gender.
- Patients with primary hepatocellular carcinoma.
- According to the "Regulations for Diagnosis and Treatment of Primary Liver Cancer (2019 Edition)" by the Health Commission of the People's Republic of China Liver cancer staging scheme, patients with Ⅲa and Ⅲb.
- The expected survival time is ≥6 months.
- Peripheral blood white blood cell count ≥3×10\^9 /L.
- Understand and voluntarily sign the informed consent form.
Exclusion
- Patients with immunodeficiency or autoimmune diseases (such as rheumatoid arthritis, systemic lupus erythematosus, multiple Primary sclerosis, insulin dependent diabetes, etc.).
- Patients with a history of other malignant tumors in the past 5 years.
- Patients who participated in other clinical trials or clinical research treatments within 3 months before this clinical study By.
- Patients who have received other cell therapy within the past 6 months.
- Patients with fever who have not effectively controlled the infection.
- Patients with high allergies or a history of severe allergies.
- Patients who are allergic to albumin.
- Patients after organ transplantation; patients who have been using or are using immunosuppressive agents for a long time.
Key Trial Info
Start Date :
January 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 31 2022
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT05242757
Start Date
January 1 2021
End Date
March 31 2022
Last Update
February 16 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zhongnan Hospital of Wuhan University
Hubei, Wuhan, China, 430071